Change of the Board of Directors in Probi

Annika Espander, Member of the Board of Directors in Probi since 2009, will join Svenska Handelsbanken  as Head of Private Banking from October 1st. In relation to this, Annika Espander resigns from all her external board assignments and she leaves the Probi board as per September 30th.

A new member of the board will be assigned at the annual general meeting in 2011.

For more information, please contact:

Per Lundin, Chairman of the Board, mobile: +46 70 5741171, e-mail:

Michael Oredsson, CEO, phone +46 46 286 89 23, mobile: +46 70 718 89 30, e-mail: 

About Probi

Probi is a leading player in the probiotic research and the development of efficient and well-documented probiotics.

The research areas include: gastrointestinal tracts, immune system, metabolic syndrome and stress and recovery. Probi’s customers are leading companies in the functional foods and dietary supplement business areas. Total income for 2009 was MSEK 65.5, of which the majority represented royalties. Probi’s share is listed on the Nasdaq OMX Stockholm, Small Cap. Probi has approximately 4,500 shareholders. For more information, please visit

About Us

Probi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas. The products are available to consumers in more than 40 countries worldwide. The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. The Probi share is listed on NASDAQ OMX Stockholm, Mid-cap. Read more on



Documents & Links